Pure Global
NCT06154135

Insulin Delivery Using the DBLG1 Closed-loop on Glycemic Control and PROMs in Adults Living With Type 1 Diabetes

Insulin Delivery Using the DBLG1 Closed-loop Algorithm on Glycemic Control and Patient-reported Outcomes in Adults Living With Type 1 Diabetes: a Multicenter Real-world Observational Study in Belgium
Erasme University Hospital·ClinicalTrials.govEnrolling by invitation
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Diabetes Mellitus, Type 1
Study type
Observational
Sponsor & location
Primary sponsor
Erasme University Hospital
Location
Aalst,Bonheiden,Brussels,Brussels,Edegem,Gent,Gilly,Leuven,Liege,Liège,Lodelinsart,Mons, Belgium
Timeline & enrollment
Phase
N/A
Start date
Dec 30, 2022
End date
Jul 30, 2026
Enrollment
165 participants
Primary outcome

Time in range

Summary

To evaluate the impact of the DBLG1 hybrid closed-loop system on glycemic control and
 patient-reported outcomes in adults living with type 1 diabetes under real-life conditions.

ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06154135
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06154135 through Pure Global AI's free database. This phase not specified trial is sponsored by Erasme University Hospital and is currently Enrolling by invitation. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 165 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.